10-Q: Hestia Insight Inc. Reports Q1 2024 Results with Reduced Operating Loss

Hestia Insight Inc. reported a net loss of $24,699 for the first quarter of 2024, an improvement compared to the $153,913 loss in the same period last year, driven by increased consulting revenue and reduced operating expenses.

Summary

• Hestia Insight Inc. reported a net loss of $24,699 for the three months ended February 29, 2024, compared to a net loss of $153,913 for the same period in 2023.
• The company's consulting revenue increased significantly to $38,000 in Q1 2024 from $500 in Q1 2023.
• Operating expenses decreased to $72,851 in Q1 2024 from $127,331 in Q1 2023, primarily due to reduced professional fees.
• The company's cash and cash equivalents increased slightly to $97,856 as of February 29, 2024, from $93,890 as of November 30, 2023.
• A related party note payable of $50,375 was established during the quarter.
• The company's total assets were $214,493 and total liabilities were $61,068 as of February 29, 2024.
• The company had 27,939,260 shares of common stock issued and outstanding as of February 29, 2024.

Sentiment

Score: 6

Explanation: The document shows improvement in financial performance with reduced losses and increased revenue, but the company still faces significant challenges, including the need for additional capital and ineffective disclosure controls. The going concern warning is also a concern.

Positives

• The company experienced a significant reduction in net loss compared to the same quarter last year.
• Consulting revenue increased substantially, indicating potential growth in the company's core business.
• Operating expenses were significantly reduced, demonstrating improved cost management.
• The company's cash position saw a slight increase, providing some financial stability.
• The company has made progress in reducing professional fees.

Negatives

• The company continues to operate at a loss, with a net loss of $24,699 for the quarter.
• The company has an accumulated deficit of $781,227.
• The company's disclosure controls and procedures were deemed ineffective.
• The company is dependent on debt and equity financing to fund its operations.
• The company's auditors have raised concerns about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company has a limited operating history and has not yet established an ongoing source of revenue sufficient to cover its operating costs.
• The company's disclosure controls and procedures were deemed ineffective, indicating potential weaknesses in financial reporting.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
• The company faces competition in its consulting business and may face competition in future ventures.

Future Outlook

The company intends to pursue the acquisition and development of healthcare-related technologies through acquisitions, licensing, or joint ventures, and will also consider investing in certain technologies. The company will need to raise additional capital to fund its operations and growth.

Management Comments

• Management is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.
• Management believes that it will be successful in its capital formation and planned operating activities.
• Management has concluded that the company's disclosure controls and procedures were ineffective as of February 29, 2024, due to limited resources and employees.

Industry Context

The company operates in the healthcare and biotech sectors, which are highly regulated and subject to rapid change. The company's focus on micro and small-cap companies with limited access to capital is a niche market within these sectors. The company also operates in the healthy food, beverage and wellness products industry and the smart vending machine industry.

Comparison to Industry Standards

• The company's consulting revenue of $38,000 is low compared to established consulting firms in the healthcare and biotech sectors.
• The company's net loss of $24,699 is not unusual for a development-stage company, but the accumulated deficit of $781,227 is a concern.
• The company's cash position of $97,856 is relatively low, indicating a need for additional capital.
• The company's reliance on related party loans is not uncommon for early-stage companies, but it can be a risk factor.
• The company's ineffective disclosure controls and procedures are a significant concern and need to be addressed.

Related Party Transactions

• On January 15, 2024, the Company entered into a $50,000 note payable to ECL Capital Partners Corp, a related party.

Stakeholder Impact

• Shareholders face the risk of dilution if the company issues additional equity.
• Employees may be impacted by the company's financial instability.
• Customers may be impacted by the company's ability to provide services.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company needs to improve its disclosure controls and procedures.
• The company needs to continue to develop its business plan and generate revenue.
• The company needs to explore strategic acquisitions and partnerships.

Key Dates

Keywords

consulting, healthcare, biotech, vending, financial results, operating expenses, net loss, revenue, capital markets, strategic acquisitions